Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Change in Account Payables (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Change in Account Payables data on record, last reported at -$241188.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 64.18% year-over-year to -$241188.0; the TTM value through Sep 2025 reached -$346606.0, down 153.14%, while the annual FY2024 figure was -$149935.0, 111.35% down from the prior year.
  • Change in Account Payables reached -$241188.0 in Q3 2025 per COEP's latest filing, down from -$91832.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $937694.0 in Q4 2023 and bottomed at -$241188.0 in Q3 2025.
  • Average Change in Account Payables over 4 years is $43569.6, with a median of $23671.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: soared 545.43% in 2023, then tumbled 269.3% in 2024.
  • A 4-year view of Change in Account Payables shows it stood at -$228851.0 in 2022, then skyrocketed by 509.74% to $937694.0 in 2023, then crashed by 85.55% to $135521.0 in 2024, then crashed by 277.97% to -$241188.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$241188.0 in Q3 2025, -$91832.0 in Q2 2025, and -$149107.0 in Q1 2025.